Welcome to our dedicated page for Lilly Eli & Co news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & Co stock.
Eli Lilly and Company (NYSE: LLY) generates frequent news across cardiometabolic health, oncology, immunology, obesity and manufacturing expansion. This page aggregates recent press releases and third-party coverage so readers can follow how Lilly’s medicines, clinical programs and corporate actions are evolving over time.
Recent updates show Lilly reporting Phase 3 results for multiple late-stage assets. In obesity and cardiometabolic health, the company has shared topline data from ATTAIN-MAINTAIN, a Phase 3 trial of orforglipron, an investigational once-daily oral GLP-1 receptor agonist, for weight maintenance after prior treatment with injectable incretin therapies. Lilly has also reported results from TRIUMPH-4, a Phase 3 trial of retatrutide, an investigational triple agonist targeting GIP, GLP-1 and glucagon receptors, in adults with obesity or overweight and knee osteoarthritis, with co-primary endpoints in weight loss and pain reduction.
In immunology, Lilly has announced positive topline results from the TOGETHER-PsA Phase 3b trial, which evaluated concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) versus Taltz alone in adults with active psoriatic arthritis and obesity or overweight with at least one weight-related condition. The company reports that the combination met the primary endpoint and all key secondary endpoints, supporting an integrated approach to treating psoriatic arthritis and obesity.
Oncology news includes updated EMBER-3 data for Inluriyo (imlunestrant) as monotherapy and in combination with Verzenio (abemaciclib) in ER-positive, HER2-negative advanced breast cancer, and Phase 3 BRUIN CLL-313 results showing that Jaypirca (pirtobrutinib) significantly reduced the risk of progression or death versus chemoimmunotherapy in treatment-naïve CLL/SLL without 17p deletions.
Corporate and strategic news items cover Lilly’s planned acquisition of Ventyx Biosciences, completion of the Adverum Biotechnologies tender offer, a strategic collaboration with Aktis Oncology, and a major manufacturing investment in a new active pharmaceutical ingredient facility in Huntsville, Alabama. Investors and observers can use this news feed to monitor clinical milestones, regulatory submissions, acquisitions, collaborations, financing activities and manufacturing expansions related to LLY.
Eli Lilly and Company (NYSE: LLY) will participate in the Cowen Health Care Conference on March 8, 2022. Anat Ashkenazi, Lilly's CFO, will engage in a virtual fireside chat at 10:30 a.m. Eastern Time. A live audio webcast will be accessible on Lilly's Investor website, with a replay available for 90 days. Lilly is dedicated to creating high-quality medicines and enhancing community well-being through philanthropy. For more details, visit www.lilly.com.
The FDA has approved Jardiance (empagliflozin) 10 mg for reducing the risk of cardiovascular death and hospitalization for heart failure in adults. This marks a significant advancement for nearly 3 million U.S. adults with heart failure with preserved ejection fraction, expanding treatment options in a sector with limited alternatives. Jardiance previously received approval for heart failure with reduced left ventricular ejection fraction. The approval is based on the EMPEROR-Preserved phase III trial, which showed a 21% risk reduction in cardiovascular events.
Eli Lilly and Company (NYSE: LLY) has launched the Lilly Institute for Genetic Medicine with a $700 million investment to establish a new facility in Boston Seaport. This initiative aims to advance RNA-based therapeutics, leveraging existing expertise from its 2020 acquisition of Prevail Therapeutics. The Boston site plans to grow its team from 120 to over 250 specialists over the next five years. Additionally, the facility will support biotech start-ups, potentially creating 150 new jobs. The Institute is expected to enhance research in neurodegenerative diseases.
In the pivotal LUCENT-1 Phase 3 study, Eli Lilly's mirikizumab demonstrated statistically superior clinical remission rates at 12 weeks in patients with moderately-to-severely active ulcerative colitis, achieving 24.2% versus 13.3% for placebo (p=0.00006). Key secondary endpoints also showed significant improvements, with 63.5% of patients responding to treatment. Mirikizumab's safety profile was consistent with previous studies, reporting lower serious adverse events (2.8% vs. 5.3% for placebo). Lilly plans to submit a Biologics License Application to the FDA in early 2022.
Eli Lilly and Company (NYSE: LLY) has launched a new education campaign aimed at raising awareness of breast cancer recurrence risks. Collaborating with organizations like Breastcancer.org and Living Beyond Breast Cancer, the initiative focuses on individuals diagnosed with hormone receptor-positive, HER2-negative early breast cancer. With over 290,000 expected diagnoses in the U.S. in 2022, the campaign provides resources to help patients understand individual risk factors for recurrence. Educational materials include a digital fact sheet and patient conversation guide.
Eli Lilly (NYSE: LLY) announced that the FDA has granted Emergency Use Authorization (EUA) for its monoclonal antibody, bebtelovimab, to treat mild-to-moderate COVID-19 in high-risk adults and pediatric patients. The treatment is authorized for patients with positive SARS-CoV-2 tests who lack suitable alternatives. The recommended dose is 175 mg via intravenous injection. Eli Lilly has secured a supply agreement with the U.S. government for 600,000 doses, valued at approximately $720 million. Bebtelovimab retains efficacy against Omicron and other variants of concern.
Eli Lilly and Company (NYSE: LLY) announced a contract with the U.S. government to supply up to 600,000 doses of the investigational COVID-19 treatment, bebtelovimab, for at least $720 million. The agreement is contingent on the drug receiving Emergency Use Authorization (EUA) from the FDA, a request that has been submitted. The projected revenue impact for 2022 is at least $720 million, with an estimated $0.20 in earnings per share (EPS). Bebtelovimab demonstrates strong efficacy against COVID-19 variants, maintaining full neutralizing activity against Omicron and other variants of concern.
Eli Lilly and Company (NYSE: LLY) has appointed Cynthia Cardona as president of the Eli Lilly and Company Foundation and senior director of social impact. Cardona will lead initiatives focused on racial justice, education, and global health. With experience dating back to 2001, she has held various leadership roles within the company, including chief marketing officer for Lilly Japan. The Foundation, established in 1968, aims to improve health and educational opportunities while addressing racial inequities. Forward-looking statements in the PR highlight potential risks linked to leadership changes.
Eli Lilly and Company (LLY) reported strong financial results for Q4 and the full year 2021, showcasing an 8% revenue increase in Q4 to $8 billion and a 15% annual growth to $28.3 billion. The company highlighted significant growth in key products, including Trulicity and Taltz. However, net income decreased by 18% in Q4 and 10% for the year, primarily due to reduced other income and increased operating expenses. Lilly continues to pursue an exciting pipeline and expects 2022 EPS in the range of $8.00 to $8.15, affirming confidence in future growth.
Eli Lilly and Company (NYSE: LLY) has partnered with UNICEF to improve health outcomes for 10 million children and adolescents suffering from chronic non-communicable diseases (NCDs) by 2025. Lilly will contribute $14.4 million to enhance healthcare systems and support health workers in Bangladesh, Malawi, Nepal, the Philippines, and Zimbabwe. This collaboration aims to combat diseases like diabetes and cancer, addressing the crisis where nearly one million children under 20 die annually due to often treatable conditions.